- Home
- CBUS
CBUS
Cibus Inc.
as 07-26-2024 4:00pm EST
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 212.4M | IPO Year: | 2017 |
| Target Price: | $23.50 | AVG Volume (30 days): | 255.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -25.38 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.41 - $23.18 | Next Earning Date: | 08-07-2024 |
| Revenue: | $2,320,000 | Revenue Growth: | 1289.22% |
| Revenue Growth (this year): | 21.63% | Revenue Growth (next year): | 301.09% |
Stock Insider Trading Activity of Cibus Inc. (CBUS)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Gocal Gregory Francis William | CBUS | Chief Scientific Officer & EVP | Jul 15 '24 | Sell | $10.01 | 2,000 | $20,022.60 | 314,844 | SEC Form 4 |
| RIGGS RORY B | CBUS | Chief Executive Officer | Dec 12 '23 | Buy | $10.58 | 517,107 | $5,470,992.06 | 1,622,495 | SEC Form 4 |
Latest Cibus Inc. News
CBUS Breaking Stock News: Dive into CBUS Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Cibus Expands its Intellectual Property Coverage for Plant Gene Editing and Traits
GlobeNewswire
a month ago
Cibus' Confirms Important Milestone for Nutrient Use Efficiency Trait Development
Simply Wall St.
a month ago
Cibus Insider Ups Holding By 47% During Year
GlobeNewswire
a month ago
Cibus Announces $13.0 Million Registered Direct Offering
GlobeNewswire
2 months ago
Cibus to Participate in Upcoming June Investor Events
GlobeNewswire
2 months ago
Cibus’ White Mold (Sclerotinia) Resistance Trait Program Confirms Important Milestone for Next Generation Gene Edits in Canola
GlobeNewswire
2 months ago
Canada Added to a Growing List of Countries Regulating Cibus’ Gene Editing Technologies Similar to Conventional Breeding
GlobeNewswire
2 months ago
Cibus to Participate in the BMO Global Farm to Market Conference
Compare CBUS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CBUS Cibus Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.